Abstract

The telomere repetitive TTAGGG motif at the ends of chromosomes, serves to preserve genomic integrity and chromosomal stability. In turn, genomic instability is a hallmark of cancer—implicating telomere disturbance. Prostate cancer (PCa) shows significant ancestral disparities, with men of African ancestry at the greatest risk for aggressive disease and associated genomic instability. Yet, no study has explored the role of telomere length (TL) with respect to ancestrally driven PCa health disparities. Patient- and technically-matched tumour-blood whole genome sequencing data for 179 ancestrally defined treatment naïve PCa patients (117 African, 62 European), we assessed for TL (blood and tumour) associations. We found shortened tumour TL to be associated with aggressive PCa presentation and elevated genomic instabilities, including percentage of genome alteration and copy number gains, in men of African ancestry. For European patients, tumour TL showed significant associations with PCa driver genes PTEN, TP53, MSH2, SETBP1 and DDX11L1, while shorter blood TL (< 3200 base pairs) and tumour TL (< 2861 base pairs) were correlated with higher risk for biochemical recurrence. Concurring with previous studies linking TL to PCa diagnosis and/or prognosis, for the first time we correlated TL differences with patient ancestry with important implications for future treatments targeting telomere dysfunction.

Details

Title
The impact of telomere length on prostate cancer aggressiveness, genomic instability and health disparities
Author
Huang, Ruotian 1 ; Bornman, M. S. Riana 2 ; Stricker, Phillip D. 3 ; Simoni Brum, Ilma 4 ; Mutambirwa, Shingai B. A. 5 ; Jaratlerdsiri, Weerachai 1 ; Hayes, Vanessa M. 6 

 University of Sydney, Ancestry and Health Genomics Laboratory, Charles Perkins Centre, School of Medical Sciences, Faculty of Medicine and Health, Camperdown, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X) 
 University of Pretoria, School of Health Systems and Public Health, Faculty of Health Sciences, Pretoria, South Africa (GRID:grid.49697.35) (ISNI:0000 0001 2107 2298) 
 St Vincent’s Hospital, Department of Urology, Darlinghurst, Australia (GRID:grid.413105.2) (ISNI:0000 0000 8606 2560) 
 Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Endocrine and Tumor Molecular Biology Laboratory, Porto Alegre, Brazil (GRID:grid.8532.c) (ISNI:0000 0001 2200 7498) 
 Sefako Makgatho Health Science University, Dr George Mukhari Academic Hospital, Department of Urology, Medunsa, South Africa (GRID:grid.461049.e) 
 University of Sydney, Ancestry and Health Genomics Laboratory, Charles Perkins Centre, School of Medical Sciences, Faculty of Medicine and Health, Camperdown, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X); University of Pretoria, School of Health Systems and Public Health, Faculty of Health Sciences, Pretoria, South Africa (GRID:grid.49697.35) (ISNI:0000 0001 2107 2298); University of Manchester, Manchester Cancer Research Centre, Manchester, UK (GRID:grid.5379.8) (ISNI:0000000121662407); University of Limpopo, Turfloop Campus, Faculty of Health Sciences, Sovenga, South Africa (GRID:grid.411732.2) (ISNI:0000 0001 2105 2799) 
Pages
7706
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3030939996
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.